Objective: To assess the continued efficacy of modafinil in the treatment of excessive daytime somnolence (EDS) of narcolepsy.Background: Modafinil has been shown to be a safe and effective treatment for the EDS presented by patients with narcolepsy. However, the duration of treatment has been relatively brief, particularly considering the chronic nature of the disease. Methods: Sixty-nine patients with narcolepsy, who completed a 6-week crossover study of modafinil continued on modafinil for 16 weeks of open-label treatment (300+/-100 mg). This was followed by 2 weeks during which patients were randomly and blindly allocated to continue modafinil (M) at the same dose (n=30), or placebo (P; n=33). Results: A mean dose of 330 mg of modafinil continued to produce a significant decrease in EDS as measured by the Maintenance of Wakefulness Test (9.7+/-7.9 for P; 16.4+/-13.7 for M; P=0.009), the Epworth Sleepiness Scale (15.4+/-5.8 for P; 13.2+/-5.7 for M; P=0.023), and the number of episodes of severe somnolence and sleep reported in patient diaries (8.2+/-7.2 for P; 4.2+/-5.2 for M; P=0.017). Modafinil had no significant effects on nocturnal sleep, blood pressure, heart rate, the electrocardiogram (ECG), weight, or mood. Conclusion:Modafinil continues to be an effective and well-tolerated drug after 16 weeks of treatment.
RCT Entities:
Objective: To assess the continued efficacy of modafinil in the treatment of excessive daytime somnolence (EDS) of narcolepsy.Background: Modafinil has been shown to be a safe and effective treatment for the EDS presented by patients with narcolepsy. However, the duration of treatment has been relatively brief, particularly considering the chronic nature of the disease. Methods: Sixty-nine patients with narcolepsy, who completed a 6-week crossover study of modafinil continued on modafinil for 16 weeks of open-label treatment (300+/-100 mg). This was followed by 2 weeks during which patients were randomly and blindly allocated to continue modafinil (M) at the same dose (n=30), or placebo (P; n=33). Results: A mean dose of 330 mg of modafinil continued to produce a significant decrease in EDS as measured by the Maintenance of Wakefulness Test (9.7+/-7.9 for P; 16.4+/-13.7 for M; P=0.009), the Epworth Sleepiness Scale (15.4+/-5.8 for P; 13.2+/-5.7 for M; P=0.023), and the number of episodes of severe somnolence and sleep reported in patient diaries (8.2+/-7.2 for P; 4.2+/-5.2 for M; P=0.017). Modafinil had no significant effects on nocturnal sleep, blood pressure, heart rate, the electrocardiogram (ECG), weight, or mood. Conclusion:Modafinil continues to be an effective and well-tolerated drug after 16 weeks of treatment.
Authors: Michael J Thorpy; Jonathan R L Schwartz; Ruzica Kovacevic-Ristanovic; Roza Hayduk Journal: Psychopharmacology (Berl) Date: 2003-04-23 Impact factor: 4.530
Authors: Chiraag Thakrar; Kishankumar Patel; Grainne D'ancona; Brian D Kent; Alexander Nesbitt; Hugh Selsick; Joerg Steier; Ivana Rosenzweig; Adrian J Williams; Guy D Leschziner; Panagis Drakatos Journal: J Sleep Res Date: 2017-10-19 Impact factor: 3.981
Authors: Michael T Saletu; Peter Anderer; Gerda M Saletu-Zyhlarz; Magdalena Mandl; Oliver Arnold; Dorothea Nosiska; Josef Zeitlhofer; Bernd Saletu Journal: Eur Arch Psychiatry Clin Neurosci Date: 2004-11-12 Impact factor: 5.270
Authors: Thomas Roth; Jonathan R L Schwartz; Max Hirshkowitz; Milton K Erman; Jeffrey M Dayno; Sanjay Arora Journal: J Clin Sleep Med Date: 2007-10-15 Impact factor: 4.062
Authors: Peter T Morgan; Edward Pace-Schott; Brian Pittman; Robert Stickgold; Robert T Malison Journal: Am J Psychiatry Date: 2010-01-15 Impact factor: 18.112